Orion Corporation opens Biologics R&D Centre at Babraham Research Campus

Orion Corporation, the globally operating Finnish pharmaceutical company, has opened its Biologics R&D Centre at Babraham Research Campus.

The new centre will help to accelerate its global growth strategy and the development of innovative medicines.

Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others.

Orion’s net sales in 2024 amounted to €1,542million and the company had about 3,700 employees at the end of the year, and operates major R&D sites in Espoo and Turku in Finland s well as in New York City and Nottingham, UK.

At Babraham, the focus will be on the development of new biological and large-molecule therapies, with biologics CMC capabilities and project leadership to support the Orion biologics research projects which are moving towards clinical phase.

“Biologics are the fastest growing segment in pharma, representing huge opportunities for new innovative treatments,” says Professor Outi Vaarala, executive vice president of Innovative Medicines and Research & Development at Orion.

“Cambridge is home to Europe’s largest biomedical research hub, and establishing our own Biologics R&D Centre in the area gives us access to a pool of world-class scientific talent and opportunities for collaboration with high-profile universities.

“I am thrilled about this continued internationalisation of Orion’s R&D to build the best expertise for the future.”